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Sumnary A new two-phase test kit for faecal occult blood combining a sensitive guaiac test (Fecatwin
(S)ensitive) with an immunological test for human haemoglobin (FECA-EIA) was compared with three
current guaiac tests (Fecatest, Fecatwin, Haemoccult) in 19 colorectal cancer patients and 11 controls on a
restricted diet. A total of 43 48 h faecal samples (30 from cancer patients and 13 from controls) were collected
for quantitative determination of faecal blood loss with the 5'Cr method.
Qualitative testing revealed that FECA-EIA was the most sensitive test, giving one (3%) false negative test
result in the 30 tests on colorectal cancer patients and no false positives in the control subjects. It was also the
only test that detected low-degree tumour bleeding. Fecatest and Fecatwin S were the most sensitive guaiac
tests, giving 7 and 10% false negative test results, respectively, in the 30 colorectal cancer samples, whereas
Haemoccult and Fecatwin gave 23% false negative test results.
For screening purposes and in order to reduce costs it is suggested that only the positive test results of the
very sensitive guaiac test (Fecatwin S) should be tested with the FECA-EIA test to eliminate false positive
results. With this approach the diagnostic accuracy of the new two-phase test will be about twice as good as
for the Haemoccult test.
The detection of colorectal cancer in asymptomatic
patients has been accepted as the only effective way
of improving the prognosis of this disease (Greegor,
1967; Bassett & Goulston, 1978; Goulston &
Davidson, 1980). In large scale screening studies
faecal occult blood testing (FOBT) based on a non-
specific guaiac test has given reasonably good
results in asymptomatic patients (Gnauck, 1974;
Gilbertsen et al., 1980; Winawer et al., 1980; Blum
et al., 1983).
The vulnerability of current FOBTs to peroxidase
and pseudoperoxidase activity in food has been
widely recognized (Illingworth, 1965; Wiener &
Wiener, 1975; Bassett & Goulston, 1980; Macrae et
al., 1982). False positive results lessen the usefulness
of the tests, resulting in unnecessary examinations
and unwanted increases in costs. False negative
results are obtained because the tests are not
sufficiently sensitive. Slight bleeding of low degree
from small cancers or adenomas is therefore not
always detected (Gnauck, 1974; Kruis et al., 1979;
Macrae & St. John, 1982; Winawer et al., 1982).
The above-mentioned shortcomings of the
current FOBTs have been the main reasons for the
development of tests for specific detection of
human blood in stools. All these tests are based on
the identification of human haemoglobin (Hb) in
stools. Human Hb has been identified by means of
haemagglutination inhibition (Adams & Layman,
1974; Heinrich, 1982), radial immunodiffusion
(Barrows et al., 1976), inhibition of anti-Rh 29 by
erythrocyte stroma (Rosenfield et al., 1978) and
immunofluorescence (Vellacott et al., 1981). Most
of the reported sensitivities of these tests have been
determined in vitro.
This paper presents the clinical results obtained
with a new and specific immunological test for
human haemoglobin in faeces (FECA-EIA)
(Partanen et al., unpublished). The clinical series
comprised colorectal cancer patients and controls.
The new test has been compared with some current
guaiac-based FOBTs in subjects on restricted diet.
The in vivo sensitivity of the five tests studied was
determined by comparison with the daily blood loss
results obtained with the 5'Cr-labelled erythrocyte
method. The daily bleeding pattern of colorectal
cancers with regard to tumour location and Dukes'
staging was also studied.
Subjects and methods
The subjects comprised 19 colorectal cancer
patients (13 males and 6 females) admitted to the
hospital for elective surgery and 11 controls (7
males and 4 females). Of the controls 7 were
colorectal cancer patients serving as their own
controls and studied from 3 to 6 months
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postoperatively. All colorectal cancer patients and
controls were studied for gastro-intestinal bleeding
using both quantitative and qualitative tests after
administration of a peroxidase-free diet.
The age of the 19 colorectal cancer patients was
67+9 years (mean+s.d.) and that of the 11
controls 58+16 years. The mean delay between the
first symptoms and surgery for the colorectal cancer
patients was 7.2+5.0 months. The first symptoms
of colorectal cancer were in decreasing frequency
changes in bowel habits (n=8), abdominal pain
(n=5), anaemia (n=4), and blood in the faeces
(n=2). Of the cancer patients 5 had a tumour in
the rectum, 8 in the left hemicolon and 6 in the right
hemicolon. Two patients had 2 primary colorectal
cancers. Of the 19 colorectal malignancies 9 were
stage A (47%), 3 were B (16%), 4 were C (21%)
and 3 were stage D (16%).
Any manipulation of the tumour such as biopsy
or administration of a barium enema was strictly
avoided for one week prior to faecal collection in
order to avoid induction of bleeding. None of the
patients in the series had any history of previous
upper gastro-intestinal tract disease.
Information concerning testing and diet was
given both orally and in writing to the subjects
studied. The study delayed surgery for the cancer
patients for 5-7 days. This problem was discussed
with the ethical committee of the hospital. It was
decided that the faecal collection should start 2
days after the administration of the 51Cr-labelled
erythrocytes (Davies, 1971; Friedman, 1972) and
that only one or two 48h faecal collections should
be performed in order to delay the operation as
little as possible.
The diagnosis of colorectal cancer was confirmed
histologically in all the patients. The tumour
specimens were classified according to the modified
Dukes' method (Dukes, 1932; Turnbull et al., 1967).
The restricted diet excluded any food containing
animal blood, uncooked fish, tomatoes, ketchup,
paprika, radish, horse-radish, turnips, bananas,
cherries, cortisone, vitamin C, aspirin and other
drugs for headache and the common cold. The diet
was started 3 days prior to the faecal collection and
was continued throughout the experimental period.
One subject had not followed the diet before the
postoperative sample was taken.
The faecal samples were collected in plastic
containers with airtight caps and with a central
hollow to increase counting efficiency. After
collection, the 48h samples were homogenized and
the 5 occult blood tests were made randomly and
without knowledge of the quantitative test results.
Samples for the FECA-EIA had to be stored at
-20°C until analysed. It was found that a 6-month
period of storage did not change the results.
Fecatest, Fecatwin (S)ensitive, Fecatwin
(Labsystems Corp., Helsinki, Finland), Haemoccult
(R6hm-Pharma, F.R.G., same as Haemoccult II,
Smith Kline Diagnostics Inc., California, U.S.A.)
were used according to the instruction given by
manufacturer.
Enzyme immunoassay ofhuman haemoglobin in
faeces
The "sandwich" type solid-phase enzyme-linked
immunosorbent assay described by Engvall et al.,
(1971) was used for the detection of human specific
haemoglobin in faeces. We used a polystyrene EIA-
grade cuvette block (Labsystems Corp., Helsinki,
Finland) as a solid phase support. Affinity purified
anti-human haemoglobin immunoglobulins were
used as "capture" antibodies. The second antibody
was labelled with alkaline phosphatase enzyme. The
assay proceeds as follows:
1. Faecal fluid from the specimens is filtered
through the guaiac paper of the Fecatwin S
guaiac test into two filter slips on the inside of
the "laboratory" lid of the plastic case. When
the lid is opened the guaiac test is carried out
and the filter slips on the lid are removed and
put into presensitized polystyrene cuvettes
provided with the FECA-EIA kit.
2. After incubation the unbound and bound
patient specimen material is separated by
washing the cuvette.
3. Alkaline phosphatase-labelled marker conjugate
is added and incubated.
4. A second washing step for separation of bound
and unbound conjugate is performed.
5. Paranitrophenylphosphate, a substrate for
alkaline phosphatase, is added to the cuvettes,
which are incubated.
6. The enzyme reaction is terminated with NaOH.
7. The end-product paranitrophenol was measured
with an FP-901 photometer (Labsystems 9-
channel batch processing analyser designed to
read Labsystems EIA-grade cuvette blocks).
8. The colour intensity is directly related to the
concentration of Hb in the patient specimen.
The specificity of anti-human haemoglobin used
as both capture and second antibody was tested
with ELISA. Cow, chicken, and rabbit
haemoglobins were tested and the only cross-
reaction detected was that with rabbit haemoglobin.
The details of the method will be described
elsewhere (Partanen et al., unpublished). In the
present study both a prototype and the final kit
were used.
The FECA-EIA test was considered positive if
one of the discs gave an absorbance of <0.045 or
if the mean absorbance for the two discs was
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and could be kept stable by using freshly prepared
p-nitrophenylphosphate reagent (bottle covered with
aluminium foil) and reduced light during the test. If
the blank values are higher and the variation larger,
the absorbances indicating a positive result must be
changed to higher values. The mean absorbance
after blank reduction in samples from normal
individuals (n= 105) was 0.007+0.008 (s.d.) with
the prototype kit and 0.003+0.010 (n=216) with
the final kit. The final kit is 10-20 times more
sensitive than the prototype kit and detects between
0.01 and 0.05mg haemoglobin g-I faeces.
When 114 hospital employees between 22 and 54
years of age on a non-restricted diet were tested
(228 discs analysed), 4 subjects (3.5%) were FECA-
EIA positive with the above criteria. Of these, 3
subjects were negative with Fecatwin S. The subject
who gave positive results in both tests had extensive
haemorrhoids. One woman was menstruating and
two other subjects had minor anal disease with
slight bleeding which was detected only by the
FECA-EIA test and not with the Fecatwin S guaiac
test. Fecatwin S was found to reveal 4.4% false
positives in this material due to the influence of diet
containing animal blood, banana and tomatoes.
Further details regarding the methodology and
reliability of the procedure will be published
elsewhere.
Wilcoxon's rank sum test was used for statistical
analysis.
Results
The FECA-EIA was the most sensitive test, giving
positive test results in 97% of the 30 48h samples
from cancer patients. Only one patient, who had
two primary cancers in the left hemicolon and 9ml
blood per 100g of faeces, gave a negative result.
Fecatwin S and Fecatest were positive and
Fecatwin and Haemoccult negative in this patient.
FECA-EIA was positive when there was more than
0.7mg Hbg-1 of faeces as measured by the 5"Cr
method. Fecatest and Fecatwin S gave 7% and
10% false negative results and the sensitivity of
both tests, according to the 5"Cr studies, was 1.2-
1.7mg of Hbg-1 of faeces. Fecatest was positive in
one sample with 1.5mg Hbg-1 of faeces which
gave negative results for all other tests (Table Ia).
Fecatwin S gave 3 negative results in 3 samples
from 2 patients with slight bleeding (Table Ia).
FECA-EIA was positive in all 3 samples of these 2
patients. Fecatwin and Haemoccult both gave 23%
false negative results, indicating that they gave -7
times more false negatives than FECA-EIA and 2
or 3 times more negatives than Fecatest and
Fecatwin S.
FECA-EIA, Fecatest and Fecatwin S were
positive in all samples (n=11) from patients with
cancer in the right hemicolon whereas Fecatwin and
Haemoccult gave one false negative test. In subjects
with left hemicolon cancers FECA-EIA, Fecatest
and Fecatwin S gave 1, 2 and 3 false negative test
results, respectively, whereas Fecatwin and
Haemoccult test gave 6 false negatives out of 19
samples.
In 6 samples (20% of the samples in colorectal
cancer patients) from 5 patients the blood loss was
less than 2.7mg of Hbg-1 faeces. All these slightly
bleeding tumours were located in the left hemicolon
and rectum and only FECA-EIA gave a positive
test result in all samples. The mean bleeding in all
the cancer patients was 11.3mg of Hbg-1 faeces
and in controls 0.4mg of Hbg-1 faeces. Judged
from the results in 11 patients with two consecutive
48 h faecal samples the bleeding in these cancer
patients was rather constant (Table Ia-c).
Among the 11 control patients FECA-EIA was
the only test giving only negative test results (Table
Ic). The guaiac tests gave one false positive test (the
patient had ingested something disallowed). The
rates of false positive results with FECA-EIA and
Fecatwin S were also compared in apparently
healthy hospital personnel (see Subjects and
methods). All subjects were tested on a non-
restricted diet but were asked not to eat more than
150g meat per day. Of the 114 subjects (228 discs
analysed) 4 gave a positive FECA-EIA result
according to the given criteria; the cause of
bleeding was an anal disease. Thus, FECA-EIA did
not give false positive results. Fecatwin S gave
4.4% false positive test results due to dietary
effects.
The geometric mean levels of blood loss in right
hemicolon cancer were significantly higher than in
cancers of the left hemicolon and rectum (Table II).
There was also a significant correlation between the
Dukes' stage and the daily blood loss when A and
B stage cancers were compared with C and D stage
cancers (Table II).
Discussion
The concept put forward by Greegor (1967) that
detection of faecal occult blood in asymptomatic
patients leads to earlier diagnosis of colorectal
cancer has now been widely accepted as a
prerequisite for improved prognosis (Gnauck, 1974;
Bassett & Goulston, 1978; Gilbertsen et al., 1980;
Macrae & St. John, 1982; Winawer et al., 1982).
Favourable results in colorectal cancer screening
have also been reported using colonoscopy and
sigmoidoscopy (Gilbertsen, 1974; Winawer et al.,
1978; Kruis et al., 1979).
Gilbertsen (1974) reported a decrease in rectalTable Ia Results of in vitro tests for occult blood in faeces compared with actual bleeding measured using 5'Cr-labelled
erythrocytes in patients with cancer in the left hemicolon and rectum.
FECA-EIA
Location Bleeding Haemo- Haem-
Subjectl ofcancer globin Feca- Feca- Feca- occult Mean
sex (stage) ml/24h ml/lOOg mgg- test twin S twin (IV) absorbance Pos/Neg
PA/F Rectuma (A) 1.6 1.1 1.5 + - - - +
0.8 0.5 0.7 - - - - 0.492 +
VL/F Rectum (B) 2.8 0.9 1.2 + + - - 2.290b +
VP/M Rectum (B) 1.7 2.3 3.3 + + + + 1.745 +
VE/M Rectum (C) 3.9 3.8 5.1 + + + + 1.106 +
4.8 2.5 3.4 + + + + 0.697 +
LO/M Rectum (D) 6.5 3.7 5.2 + + + + 0.124 +
16.5 4.0 5.6 + + + + 0.223 +
KV/M Sigmoid (A) 3.0 8.5 13.3 + + + + 1.445b +
LE/M Sigmoid (A) 2.3 1.9 2.7 + + - - 0.859 +
SL/M Sigmoid (A) 2.1 3.0 4.3 + + + + 0.694 +
2.1 4.3 6.1 + + + + 0.733 +
SAP/F Sigmoid (A) 6.1 1.6 2.0 + + + + 0.037 +
LE/F Sigmoid (A) 8.8 5.3 6.8 + + + + 0.037 +
ST/M Sigmoid (A) 0.5 1.4 1.7 - - - - +
0.4 2.9 3.5 + + + + 0.103b +
KV/M Sigmoid (D) 5.3 4.7 6.1 + + + + 1.262 +
3.6 2.7 3.5 + + + + 1.262 +
VS/F Splenic 4.9 9.0 9.9 + + - - 0.027
flexure and
descending colon (D)
Geometric mean 2.8 2.7 3.6 0.370
% correct positives
based on diagnosis 89 84 68 68 95
'Polyp with cancer in situ
bDetermined with the FECA-EIA prototype
Table Ib Results of in vitro tests for occult blood in faeces compared with actual bleeding measured using 5 Cr-labelled
erythrocytes in patients with cancer in the right hemicolon.
FECA-EIA
Location Bleeding Haemo- Haem-
Subjectl ofcancer globin Feca- Feca- Feca occult mean
sex (stage) ml/24h ml/JOOg mgg 1 test twin S twin (II) absorbance Pos/Neg
PA/F Ascending 10.0 7.3 8.0 + + + + 0.145 +
colon (A) 16.5 7.2 7.9 + + + + 0.235 +
LK/M Ascending 7.0 6.4 6.6 + + - - 0.394 +
colon (B)
MK/M Ascending 42.3 20.9 23.9 + + + + 0.156b +
colon (C) 38.8 16.9 19.1 + + + + 0.161b +
BA/M Ascending 85.5 73.0 70.8 + + + + 0.119 +
colon (C) 73.5 60.5 58.7 + + + + 0.058b +
KN/M Ascending' 8.8 10.8 13.1 + + + + 0.140b +
colon (C) 25.5 17.5 21.2 + + + + 1.467 +
KA/M Caecum (D) 2.3 8.9 10.2 + + + + 0.055b
13.6 13.7 15.8 + + + + 0.038b +
Geometric mean 18.4 15.4 17.1 0.152
% correct positives
based on diagnosis 100 100 91 91 100
'In addition a small cancerous polyp in rectum
bDetermined with the FECA-EIA prototype
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Table Ic Results of in vitro tests for occult blood in faeces compared with actual bleeding measured using 5'Cr-labelled
erythrocytes in control patients.
FECA-EIA
Bleeding Haemo- Haem-
Subjectl Diagnosis globin Feca- Feca- Feca- occult Mean
Sex (procedure) ml/24h ml/lOOg mgg-' test twin S twin (II) absorbance Pos/Neg
AM/F Control 0.5 0.5 0.7 - - - - 0.0 -
0.9 0.8 1.1 - - - - 0.007 -
KT/F Control 0.9 1.0 1.4 - - - - 0.0
1.0 0.5 0.7 - - - - 0.0 -
PS/F Control 0.1 0.1 0.2 - - - - 0.0 -
SJ/M Control 0.4 0.3 0.5 - - - - 0.002 -
LO/M p.o. control 1.0 0.4 0.5 +a +a +a +a 0.0 -
(anterior resection)
VE/M p.o. control 0.1 0.05 0.1 - - - - 0.09 -
(anterior resection)
KV/M p.o. control 0.2 0.2 0.3 - - - - 0.0 -
(sigmoid resection)
ST/M p.o. control 0.3 0.2 0.3 - - - 0.022 -
(sigmoid resection)
MK/M p.o. control 4.7b 40b 4.6b - - - 0.0 -
(right hemicolectomy)
PA/F p.o. control 1.8 0.7 1.0 - - - - 0.004 -
(right hemicolectomy)
BA/M p.o. control 0.3 0.2 0.2 - - - 0.003 -
(right hemicolectomy)
Geometric mean 0.4 0.3 0.4
aFalse positive due to ingestion ofuncooked salmon
bNot included in the mean value, because of assay error.
Table II Mean excretion of Hb (mgg-1 of faeces) in colorectal cancer with
regard to tumour stage and location.
No. of No. of48h
pts faecal samples Excretion ofHb (mgg-I offaeces)a
Dukes A 8 12 3.6 (0.7-13.3)
B 3 3 3.0 (1.2-6.6)
C 4 8 17.6 (3.4-70.8)
D 4 7 7.2 (3.5-15.8)
Right hemicolon 6 11 17.1 (6.6-70.8)
Left hemicolon 8 11 4.5 (1.7-13.3)
Rectum 5 8 2.6 (0.7-5.6)
aGeometric mean (and range)
A+B vs C+D; P<0.01
Right hemicolon vs left hemicolon+rectum; P<0.001.146 M.J. TURUNEN et al.
cancer incidence after removing neoplastic polyps in
repeated sigmoidoscopies. Sigmoidoscopy alone is
not justified in colorectal cancer screening,
however, because it can reach only about half of all
colorectal malignancies. Colonoscopy is too
cumbersome, time consuming and costly for
screening purposes.
Faecal occult blood tests have been used
extensively in screening asymptomatic patients. The
colorectal cancers detected have mostly belonged to
Dukes A and B stages and should consequently
have a better 5-year survival rate than symptomatic
cases (Gnauck, 1974; Gilbertsen et al., 1980;
Winawer et al., 1980).
Most of the current FOBTs are based on the
guaiac test, giving false negative results in 9-31%
and false positive results in 2-20% (Gnauck, 1974;
Bassett & Goulston, 1978; Kruis et al., 1979;
Gilbertsen et al., 1980; Winawer et al., 1980, 1982;
Doran & Hardcastle, 1982; Macrae & St. John,
1982. The combined Fecatwin S-FECA-EIA kit
aims at eliminating all false positive results. Because
the FECA-EIA test is comparatively expensive, it is
suggested that only the Fecatwin S positive samples
should be investigated with the FECA-EIA test.
However, this will lead to some false negative test
results, which in our cancer material would have
amounted to 13% of the single tests because
10% of the samples were negative with Fecatwin S
and 3% negative with FECA-EIA. Fecatest gave a
corresponding false negative rate of 7% and both
the sensitive tests had a sensitivity limit as low as
1.2-1.7mg Hbg-1 faeces. There seems to be no
significant difference in sensitivity between
Fecatwin S and the original Fecatest (Adlercreutz et
al., 1982). Haemoccult and Fecatwin were found to
be much less sensitive, giving 23% false negative
single test results. The difference was probably not
due to homogenization of the faeces, which was
necessary in order to get comparable results,
because in a previous study the difference was
larger when non-homogenized samples were studied
(Adlercreutz et al., 1982 and in press). Quite
recently Doran et al. (1982) reported a 30% false
negative rate for Haemoccult using the standard 3-
day regimen. False negative results with
Haemoccult still occurred in 10% after a 6-day test
period. The most sensitive FOBTs all need a very
strict peroxidase-free diet (Gnauck, 1974; Morris et
al., 1976; Adlercreutz et al., 1978; Macrae et al.,
1982). Because dietary restrictions seem to be
difficult for patients to follow, even under
controlled circumstances, as in our study, the
human haemoglobin specific test appears to be
mandatory in colorectal cancer screening.
Anaemia and melaena are common clinical signs
of cancer of the right hemicolon. In the present
study the faecal samples from patients with cancer
in the right hemicolon were found to contain more
blood than those from patients with cancer in the
left hemicolon and rectum. A statistically significant
correlation between the daily blood loss and the
tumour stage was also observed. Similar results
have been reported previously by Macrae et al.
(1982).
In a trial by Songster et al. (1980) 29% of the
colorectal cancer patients did not show bleeding by
either the relatively insensitive immunological
method of Barrows et al. (1976) or the Haemoccult
II test when one or more faecal specimens were
tested. In their survey, the immunological test
proved more sensitive than the Haemoccult II test,
especially in bleeding from the colon. For rectal
bleeding, however, their immunological test was
positive in only 50% of the patients. Using a more
sensitive version of this test, Williams et al. (1982)
showed that all cancer patients had detectable Hb
in their stools but they did not quantify the daily
bleeding. This is in agreement with our results,
which indicated bleeding in 97% of the cancer
patients as judged by FECA-EIA alone and in
100% if both Fecatwin S and FECA-EIA were
performed separately. Williams et al. (1982) also
revealed that the specific test was more sensitive
than the Haemoccult II test, as shown in the
present study also. Rosenfield et al. (1978) reported
a specific test based on the inhibition of anti-Rh 29
by erythrocytic stroma in faeces. The sensitivity of
this test was equivalent to that of the Haemoccult
II test.
In the present study 20% of the cancer patients
had a blood loss of <2.7mgHbg-1 faeces. In these
patients with slight bleeding, FECA-EIA was the
only test giving 100% positive results. Measured
with the "Cr method the sensitivity limit for
FECA-EIA was 0.7mg Hbg-1 faeces. However,
this is below the true sensitivity limit of the 51Cr
method because at the level most of the
radioactivity is due to biliary excretion of 5"Cr
(Stephens & Lawrenson, 1969). Thus, in vivo
sensitivity of FECA-EIA cannot be determined
exactly because no sufficiently sensitive reference
method is available. In vitro the FECA-EIA test
detects 0.01-.05mgHb added to 1 g of faeces. The
immunological test therefore seems to be at least 10
times more sensitive than the guaiac screening test.
The test used for screening, in this case Fecatwin
S, must be as sensitive as possible in order not to
give false negative test results. This guaiac test is
sensitive, but it was still negative in 10% of the
samples (10.5% of the colorectal cancer patients)
when testing only one or two samples from each
subject. Despite this, we still recommend the use of
the combined Fecatwin S and FECA-EIA kit and
not the FECA-EIA test alone for screening because
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relatively expensive. Using Fecatwin S as a
screening test, only ,5-15% of the samples need
to be retested with FECA-EIA, depending on the
diet of the population screened. The present study
was not aimed at investigating the usefulness of the
combined kit for screening purposes, but at
comparing the test with a reference method in
normal subjects and in colorectal cancer patients,
and at determining its sensitivity and accuracy. In
our hands the immunological test proved to be
both accurate and sensitive. We suggest that three
consecutive samples be taken for screening
purposes, because in this way the percentage of
false negative results shown by Fecatwin S and
caused by non-uniform distribution of blood in the
faeces (Rosenfield et al., 1978) will probably be
reduced to <5%.
It is concluded that the new two-phase test for
occult blood in faeces is the first practical kit
available and has great potential in colorectal
cancer screening. No dietary restrictions are needed,
which will increase patient compliance. Used in the
suggested way, the test will probably lead to a good
cost-benefit ratio. Further studies under field
conditions are necessary before a final evaluation of
this test is possible.
Labsystems Corp. supplied the Fecatwin sensitive FECA-
EIA kits.
The study was supported by grants from the Medical
Research Council of the Academy of Finland (H.
Adlercreutz) and the Finnish Cancer Society (M.J.
Turunen).
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